Results 111 to 120 of about 18,555 (185)

Letter on 'Network Meta-Analysis: Comparison of Pharmacological Therapies in Compensated MASH Cirrhosis for Fibrosis Regression and MASH Resolution'. Authors' Reply. [PDF]

Aliment Pharmacol Ther
Souza M, Huang DQ, Loomba R.
europepmc   +1 more source

The Athabasca River regulates methylmercury burdens of waterbirds breeding downstream. [PDF]

Sci Rep
Chételat J, Hebert C, Demers JD, Cooke CA, McClelland C, Angell M, Bergquist B, Evans M, Fahnestock MF, Güneşli K, Greenwood S, Maclean B, McMaster M, Mundy L, Tetreault G, Thomas PJ.   +15 more
europepmc   +1 more source

Assessment of Esophageal and Gastric Varices in Patients With Cirrhosis for Clinical Trials: A Centralized Blinded Evaluation System. [PDF]

Gastro Hep Adv
Alkhouri N, Vuppalanchi R, Noureddin M, Lawitz E, Mena E, Gunn NT, Jamil K, Zuckerman S, Harrison SA, Chalasani N.   +9 more
europepmc   +1 more source

Relationship Between Metabolic and Histological Responses in People With Metabolic Dysfunction- Associated Steatohepatitis With and Without Type 2 Diabetes: Participant-Level Exploratory Analysis of the SYNERGY-NASH Trial With Tirzepatide. [PDF]

Diabetes Care
Caussy C, Cusi K, Rosenstock J, Bugianesi E, Thomas MK, Tang Y, Mather KJ, Loomba R, Sanyal AJ, Hartman ML.   +9 more
europepmc   +1 more source

Response to comment on Buse et al. Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes. Diabetes Care 2025;48:2012-2020. [PDF]

Diabetes Care
Buse JB, Kahn SE, Schlafly TK, Einhorn D.   +3 more
europepmc   +1 more source

Letter: Safety and Tolerability of Injectable Extended-Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol-Associated Liver Disease-Authors' Reply. [PDF]

Aliment Pharmacol Ther
Díaz LA, Loomba R.
europepmc   +1 more source

Consistent efficacy of efruxifermin across PNPLA3 genotypes in phase 2b trials in MASH. [PDF]

Hepatology
Chalasani N, Tillman EJ, Billes SK, Rolph T, Noureddin M.   +4 more
europepmc   +1 more source